Ivlv-X1

lentiviral vector-based gene therapy for SCID-X1 · Shenzhen Geno-Immune Medical Institute

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ivlv-X1, covering 2025-09-09 to 2025-09-09. Get the full timeline:

Most recent: Clinical Trial Update: SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection [Phase 1, Phase 2]